

Chloroquine and hydroxychloroquine are associated with COVID-19 mortality: a systematic review and meta-analysis

Drug Design, Development and Therapy

Volume 12, 1685-1695

DOI: [10.2147/dddt.s166893](https://doi.org/10.2147/dddt.s166893)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1 ^β Expression in Primary Mouse Cardiac Fibroblasts. <i>Frontiers in Immunology</i> , 2019, 10, 1285.	2.2	10
2	Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2019, 8, 796.	1.0	31
3	Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , 2019, 286, 458-468.	2.7	22
4	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 2019, , 293-300.	0.6	2
5	Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e19-e19.	0.5	3
6	Response to Letter to the Editor by Bartoloni et al: "Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome". <i>Journal of Internal Medicine</i> , 2020, 287, 216-217.	2.7	0
7	Hydroxychloroquine and QT prolongation: reassuring data in approved indications. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa044.	0.3	9
8	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. , 2020, 216, 107672.		52
9	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <i>Life Sciences</i> , 2020, 262, 118541.	2.0	12
10	Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e154-e154.	0.5	3
11	Can HCQ Be Considered a "Safe Weapon" for COVID-19 in the Indian Population?. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1057-1063.	0.3	2
12	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. <i>Function</i> , 2020, 1, .	1.1	12
13	Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. <i>Medicina (Lithuania)</i> , 2020, 56, 386.	0.8	56
14	Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1359-1362.	0.8	1
15	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. <i>New Microbes and New Infections</i> , 2020, 37, 100747.	0.8	17
16	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. <i>Life Sciences</i> , 2020, 254, 117775.	2.0	35
17	Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2322-2324.	2.5	18
18	Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 15, 820-830.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. <i>AAPS Journal</i> , 2020, 22, 86.	2.2	23
20	Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 241-246.	1.8	357
21	Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2020, 23, 177-181.	2.9	41
22	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 755-759.	2.5	31
23	Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 930-937.	0.6	16
24	Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice. <i>Life Sciences</i> , 2021, 264, 118450.	2.0	20
25	An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. <i>International Journal of Infectious Diseases</i> , 2021, 103, 599-606.	1.5	8
26	Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1774-1783.	0.9	12
27	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021, 41, 257-273.	1.5	3
28	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 576093.	1.6	17
29	Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state. <i>Lupus Science and Medicine</i> , 2021, 8, e000467.	1.1	4
30	Effect of Hydroxychloroquine on Lipid Levels: A Systematic Review and Metaanalysis. <i>Current Pharmaceutical Design</i> , 2021, 27, 4133-4139.	0.9	5
32	Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. <i>Lupus Science and Medicine</i> , 2021, 8, e000515.	1.1	7
33	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021, 12, 699949.	1.6	15
34	Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	4
35	Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1508-1511.	1.0	8
36	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. <i>Biomedicines</i> , 2021, 9, 122.	1.4	5
38	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. <i>Current Pharmaceutical Design</i> , 2020, 26, 4467-4485.	0.9	34

#	ARTICLE	IF	CITATIONS
39	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). <i>Current Vascular Pharmacology</i> , 2020, 18, 455-462.	0.8	4
40	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. <i>Indian Journal of Medical Research</i> , 2021, 153, 219.	0.4	5
41	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <i>Drugs in Context</i> , 2019, 8, 1-12.	1.0	37
42	Antimalarials – old drugs are new again. <i>Postepy Dermatologii I Alergologii</i> , 0, , .	0.4	0
43	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , 2021, 73, 2151-2160.	2.9	19
44	Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity. <i>Journal of Infection and Public Health</i> , 2021, 14, 1686-1692.	1.9	9
45	Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 271.	1.6	5
46	Cardiovascular Events, Sleep Apnoea, and Pulmonary Hypertension in Primary Sjögren's Syndrome: Data from the French Health Insurance Database. <i>Journal of Clinical Medicine</i> , 2021, 10, 5115.	1.0	9
47	Targeting lysosomes in human disease: from basic research to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 379.	7.1	58
49	Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681327.	1.1	1
50	Carotid Artery Pathology in Inflammatory Diseases. <i>American Journal of the Medical Sciences</i> , 2021, , .	0.4	0
51	Cardiovascular Outcomes in Systemic Lupus Erythematosus. <i>Current Cardiology Reports</i> , 2022, 24, 75.	1.3	2
52	A review study of Antibiotics with Antiviral and Anti-inflammatory Potential against Covid-19. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2022, 17, .	0.4	1
53	Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151946.	1.6	4
54	Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2022, 44, 309-324.	2.8	18
55	The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, 35, 51-53.	0.1	0
56	Effect of hydroxychloroquine and chloroquine on syncytial differentiation and autophagy in primary human trophoblasts. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112916.	2.5	4
57	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 76-83.	0.1	1

#	ARTICLE	IF	CITATIONS
58	Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681327.	1.1	8
59	Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center. <i>Rheumatology International</i> , 2022, , 1.	1.5	1
62	Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. <i>Medicina (Lithuania)</i> , 2022, 58, 571.	0.8	4
63	Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study. <i>Clinical Rheumatology</i> , 0, , .	1.0	3
64	Prevalence of and Risk Factors for Major Comorbidities of Systemic Lupus Erythematosus Using Data from a Multicenter Chinese Cohort Registry: A Cross-Sectional Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
65	The Association of Hydroxychloroquine Dosing with Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 0, , .	1.5	0
66	The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0
67	Adverse events in rheumatoid arthritis patients under antimalarial treatmentâ€”Is there cardiovascular compromise?. <i>Frontiers in Drug Safety and Regulation</i> , 0, 2, .	0.5	0
68	Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1331.	1.8	6
69	Fe(VI) activation system mediated by a solar-driven TiO2 nanotubes electrode for CLQ degradation: Performances, mechanisms and pathways. <i>Journal of Hazardous Materials</i> , 2023, 452, 131274.	6.5	9
70	Systemic Lupus Erythematosus May Be a Risk Factor for <scp>Antimalarialâ€”Induced</scp> Retinopathy Compared With Other Rheumatologic Diseases. <i>ACR Open Rheumatology</i> , 2023, 5, 173-179.	0.9	2
71	Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus. <i>European Journal of Internal Medicine</i> , 2023, 112, 70-76.	1.0	0
78	Cutaneous Lupus Erythematosus: Review and Considerations for Older Populations. <i>Drugs and Aging</i> , 0, , .	1.3	0
80	Vascular damage in systemic lupus erythematosus. <i>Nature Reviews Nephrology</i> , 2024, 20, 251-265.	4.1	1